

Ultragenyx Pharmaceutical Inc.

Form 3

January 30, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â KAKKIS EMIL D

(Last) (First) (Middle)

C/O ULTRAGENYX
PHARMACEUTICAL
INC.,Â 60 LEVERONI COURT

(Street)

NOVATO,Â CAÂ 94949

(City) (State) (Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

01/30/2014

3. Issuer Name and Ticker or Trading Symbol

Ultragenyx Pharmaceutical Inc. [RARE]

4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☒ 10% Owner☒ Officer ☐ Other
(give title below) (specify below)

See Remarks

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

2,552,241

I

By Emil Kakkis and Jenny
Soriano Living Trust, Dated June
18, 2009Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date3. Title and Amount of
Securities Underlying

4. Conversion

5. Ownership

6. Nature of Indirect
Beneficial

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 3

	(Month/Day/Year)		Derivative Security (Instr. 4)		or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	Â (1)	Â (1)	Common Stock	1,956,686 (1)	\$ (1)	D	Â
Warrant to Purchase Series A Preferred Stock (Right to Buy)	Â (2)	06/30/2020	Common Stock	260,688	\$ 0.959	D	Â
Warrant to Purchase Series A Preferred Stock (Right to Buy)	Â (2)	06/14/2021	Common Stock	78,206	\$ 0.959	D	Â
Warrant to Purchase Series A Preferred Stock (Right to Buy)	Â (2)	06/14/2021	Common Stock	130,344	\$ 0.959	D	Â
Stock Option (Right to Buy)	Â (3)	10/31/2023	Common Stock	47,854	\$ 6.8646	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KAKKIS EMIL D C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949	Â X	Â X	Â See Remarks	Â

Signatures

By: /s/ Emil D. Kakkis, M.D.,
Ph.D. 01/30/2014

Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each share of Series A Convertible Preferred Stock automatically converts into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and has no expiration date. The number of underlying shares of common stock reported in Column 3 does not reflect this 1-for-3.1345 reverse stock split, pursuant to which each share of Series A Convertible Preferred Stock will become convertible into 0.3190 of a share of common stock.

(2) Each share of Series A Convertible Preferred Stock automatically converts into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and has no expiration date. The number of underlying shares of common stock reported in Column 3 does not reflect this 1-for-3.1345 reverse stock split, pursuant to which each share of Series A Convertible Preferred Stock will become convertible into 0.3190 of a share of common stock. The warrant became exercisable on June 16, 2011. If the warrant is not exercised prior to the closing of the Company's initial public offering, the warrant will become automatically exercisable for shares of Common Stock instead of shares of Series A Convertible Preferred Stock.

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 3

- (3) 1/4th of the option shall vest one year from November 1, 2013 and then the remaining shares vest monthly until November 1, 2017, provided the Reporting Person has not terminated services with the Issuer.

Â

Remarks:

PresidentÂ andÂ ChiefÂ ExecutiveÂ Officer

ExhibitÂ List

ExhibitÂ 24Â -Â LimitedÂ PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.